| 发明名称 | Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof | ||
| 摘要 | Disclosed herein are compositions and methods for treating a psychiatric disorder or symptoms thereof in a patient. The compositions comprise a compound that modulates KCNQ (Kv7) potassium channel activity and the methods include administering an effective amount of the compound that modulates KCNQ (Kv7) potassium channel activity. | ||
| 申请公布号 | US9017735(B2) | 申请公布日期 | 2015.04.28 |
| 申请号 | US201012793330 | 申请日期 | 2010.06.03 |
| 申请人 | Marquette University | 发明人 | Ghasemzadeh Mohammadhossein Behnam |
| 分类号 | A61K31/444;A61K31/451;A61K31/454;A61K31/496;A61K31/519;A61K31/53;A61K31/5415;A61K31/5513;A61K31/554;A61K33/00;A61P25/00;A61P25/18;A61P25/36;A61K31/4427;A61K31/122;A61K31/4025;A61K31/4409;A61K31/4725 | 主分类号 | A61K31/444 |
| 代理机构 | Andrus Intellectual Property Law, LLP | 代理人 | Andrus Intellectual Property Law, LLP |
| 主权项 | 1. A method for treating a negative symptom of a psychiatric disorder in a psychiatric patient exhibiting the negative symptom, the method comprising administering an effective amount of a compound that inhibits KCNQ (Kv7) potassium channel activity to the psychiatric patient exhibiting the negative symptom, wherein the compound is linopirdine, XE991, DMP543, or a deuterated derivative or analog thereof. | ||
| 地址 | Milwaukee WI US | ||